- All sections
- C - Chemistrymetallurgy
- C12N - Microorganisms or enzymescompositions thereofpropagating, preserving, or maintaining microorganismsmutation or genetic engineeringculture media
- C12N 9/68 - Plasmin, i.e. fibrinolysin
Patent holdings for IPC class C12N 9/68
Total number of patents in this class: 86
10-year publication summary
|
8
|
6
|
5
|
4
|
8
|
6
|
6
|
3
|
9
|
1
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Modernatx, Inc. | 1279 |
9 |
| Previpharma Consulting GmbH | 18 |
8 |
| Gentium S.r.l. | 36 |
6 |
| Kedrion Biopharma Inc. | 16 |
5 |
| Monash University | 736 |
5 |
| ThromboGenics NV | 13 |
4 |
| Kedrion S.p.A. | 53 |
3 |
| Bioatla, Inc. | 117 |
3 |
| Immunofyx | 3 |
3 |
| CSL Behring AG | 187 |
2 |
| Grifols Therapeutics Inc. | 17 |
2 |
| Talecris Biotherapeutics, Inc. | 10 |
2 |
| The University of British Columbia | 1557 |
2 |
| ProMetic BioTherapeutics, Inc. | 9 |
2 |
| Talengen International Limited | 86 |
2 |
| Versiti Blood Research Institute Foundation, Inc. | 33 |
2 |
| E. I. du Pont de Nemours and Company | 3452 |
1 |
| Massachusetts Institute of Technology | 10313 |
1 |
| Korea Institute of Science and Technology | 2260 |
1 |
| Anhui New Star Pharmaceutical Development Co., Ltd. | 13 |
1 |
| Other owners | 22 |